Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › tafamidis

tafamidis

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of tafamidis

8 trials tracked of tafamidis: 6 in phase 3 or 4 and 4 with published results. The most-cited published study has 109 citations.

8Trials tracked
6Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 1 Phase 3 5 Other / NA 2
  1. Phase 3 Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis Completed · 109 cited
  2. Phase 3 Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy Completed · 63 cited
  3. Phase 3 Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy Completed · 21 cited
  4. Phase 4 A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Completed
  5. Phase 3 Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy Completed
  6. Phase 3 The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin Completed
Show 2 more trials
  1. N/A A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis Completed
  2. N/A Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045. Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Acoramidis associated with lower diuretic intensification in transthyretin amyloid cardiomyopathy
Cardiology Cohort
Acoramidis associated with lower diuretic intensification in transthyretin amyloid cardiomyopathy New Heart Drug Shows Lower Risk of Hospitalization vs Older Option
In this retrospective cohort study using US claims data, acoramidis was associated with a lower risk of diuretic intensification and a compo…
A new heart drug cut diuretic needs and hospitalizations more than the older option in early real-world use.
medRxiv Apr 27, 2026
Observational cohort finds high cardiac involvement and variable treatment patterns in hATTR patients
Neurology Cohort
Observational cohort finds high cardiac involvement and variable treatment patterns in hATTR patients Heart Treatment Often Misses Nerve Damage in This Group
This single-center retrospective cohort study of 54 patients with hereditary transthyretin amyloidosis (hATTR) found 94.4% had cardiac invol…
Heart patients with a common African American gene variant often get nerve damage missed, leaving tingling hands untreated while doctors foc…
medRxiv Apr 19, 2026